Literature DB >> 6379048

A novel antigenic cell surface protein associated with T200 is involved in the post-activation stage of human NK cell-mediated lysis.

G F Burns, J A Werkmeister, T Triglia.   

Abstract

A monoclonal antibody, 9.1C3, was used to investigate the mechanism of natural killer (NK) cell-mediated lysis. In addition to blocking NK cell function, the antibody blocked antibody-dependent cellular cytotoxicity against the K562 target cell at the effector cell level. The stage at which 9.1C3 antibody inhibited cytolysis was established with a Ca++ pulse technique, whereby it was shown that the antibody inhibited killing at a discrete step after the Ca++-dependent programming for lysis. The 9.1C3 antigen appeared to be associated with the T200 glycoprotein complex. Thus the 66 and 77 Kd proteins detected by 9.1C3 were also precipitated with a monoclonal antibody to T200, and in sequential immunoprecipitations, 9.1C3 antibody removed these bands from immunoprecipitates with antibody to T200. Also, in co-modulation studies, it was found that antibody to T200 co-capped the 9.1C3 antigen but that capping with 9.1C3 antibody did not induce co-modulation of the T200 antigen. Expression of the 9.1C3 and T200 antigens on different cell types, however, was not identical, and the 9.1C3 antibody did not immunoprecipitate high m.w. proteins in the region of 200 Kd. Functionally, in NK cell killing studies, the antibody to T200 used alone did not block but was synergistic with the 9.1C3 antibody. The differential effect of the enzymes pronase and trypsin on the cell surface expression of the 9.1C3 and T200 antigens reflected the ability of these enzymes to inhibit NK cell killing. These data suggest that the 9.1C3 antigen participates in a late event in the cytolytic pathway.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6379048

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen.

Authors:  G C Starling; S E Davidson; J L McKenzie; D N Hart
Journal:  Immunology       Date:  1987-07       Impact factor: 7.397

2.  Further data on the selective expression of Ly-5 isoforms.

Authors:  Y Saga; K Furukawa; P Rogers; J S Tung; D Parker; E A Boyse
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

3.  Studies on natural, antibody-dependent, and interleukin-2-activated killer-cell activity of a patient with mucolipidosis III as a test of the mannose-6-phosphate lytic acceptor hypothesis.

Authors:  J A Werkmeister; H F Pross
Journal:  J Clin Immunol       Date:  1985-07       Impact factor: 8.317

4.  Mass-spectrometry-based draft of the Arabidopsis proteome.

Authors:  Julia Mergner; Martin Frejno; Markus List; Michael Papacek; Xia Chen; Ajeet Chaudhary; Patroklos Samaras; Sandra Richter; Hiromasa Shikata; Maxim Messerer; Daniel Lang; Stefan Altmann; Philipp Cyprys; Daniel P Zolg; Toby Mathieson; Marcus Bantscheff; Rashmi R Hazarika; Tobias Schmidt; Corinna Dawid; Andreas Dunkel; Thomas Hofmann; Stefanie Sprunck; Pascal Falter-Braun; Frank Johannes; Klaus F X Mayer; Gerd Jürgens; Mathias Wilhelm; Jan Baumbach; Erwin Grill; Kay Schneitz; Claus Schwechheimer; Bernhard Kuster
Journal:  Nature       Date:  2020-03-11       Impact factor: 49.962

5.  The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45.

Authors:  L A Terry; M H Brown; P C Beverley
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

6.  TLiSA1, a human T lineage-specific activation antigen involved in the differentiation of cytotoxic T lymphocytes and anomalous killer cells from their precursors.

Authors:  G F Burns; T Triglia; J A Werkmeister; C G Begley; A W Boyd
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

Review 7.  Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Mol Ther Oncolytics       Date:  2021-11-29       Impact factor: 7.200

Review 8.  NK cell autoreactivity and autoimmune diseases.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Front Immunol       Date:  2014-02-04       Impact factor: 7.561

Review 9.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.